The forecasted antiarrhythmic medicine sales in Canada show a gradual decline from 2024 to 2028, starting at $17.1 million in 2024 and decreasing to $16.5 million in 2028. This represents a mild year-on-year decrease, averaging about 0.74% decline annually. In 2023, the market was steady, standing at $17.2 million, indicating a slight downward trend projected over the next few years. The Compound Annual Growth Rate (CAGR) from 2024 to 2028 is negative, reflecting a market contraction, likely driven by factors such as market saturation, increased generic competition, or shifting treatment practices.
Future trends to watch for include:
- Impact of generic drugs on market margins and sales.
- Innovation in treatment protocols and emerging alternatives to antiarrhythmic drugs.
- Regulatory changes and healthcare policy developments in Canada.
